DE69625696T2 - Verwendung eines thienotriazoldiazepins zur erhöhung des apolopoproteins a-i niveaus - Google Patents

Verwendung eines thienotriazoldiazepins zur erhöhung des apolopoproteins a-i niveaus

Info

Publication number
DE69625696T2
DE69625696T2 DE69625696T DE69625696T DE69625696T2 DE 69625696 T2 DE69625696 T2 DE 69625696T2 DE 69625696 T DE69625696 T DE 69625696T DE 69625696 T DE69625696 T DE 69625696T DE 69625696 T2 DE69625696 T2 DE 69625696T2
Authority
DE
Germany
Prior art keywords
compound
pct
apo
levels
increase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69625696T
Other languages
German (de)
English (en)
Other versions
DE69625696D1 (de
Inventor
Herman Kempen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE69625696D1 publication Critical patent/DE69625696D1/de
Application granted granted Critical
Publication of DE69625696T2 publication Critical patent/DE69625696T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
DE69625696T 1995-09-09 1996-08-30 Verwendung eines thienotriazoldiazepins zur erhöhung des apolopoproteins a-i niveaus Expired - Fee Related DE69625696T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95114163 1995-09-09
PCT/EP1996/003814 WO1997009048A1 (en) 1995-09-09 1996-08-30 Use of a thienotriazolodiazepine to increase apolipoprotein a-i levels

Publications (2)

Publication Number Publication Date
DE69625696D1 DE69625696D1 (de) 2003-02-13
DE69625696T2 true DE69625696T2 (de) 2003-10-16

Family

ID=8219597

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69625696T Expired - Fee Related DE69625696T2 (de) 1995-09-09 1996-08-30 Verwendung eines thienotriazoldiazepins zur erhöhung des apolopoproteins a-i niveaus

Country Status (14)

Country Link
US (1) US5854238A (https=)
EP (1) EP0853480B1 (https=)
JP (1) JPH11512107A (https=)
KR (1) KR19990044460A (https=)
CN (1) CN1101680C (https=)
AT (1) ATE230600T1 (https=)
AU (1) AU725249B2 (https=)
BR (1) BR9610390A (https=)
CA (1) CA2230477A1 (https=)
DE (1) DE69625696T2 (https=)
DK (1) DK0853480T3 (https=)
ES (1) ES2188783T3 (https=)
TR (1) TR199800406T1 (https=)
WO (1) WO1997009048A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6518412B1 (en) * 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6253569B1 (en) * 1999-05-07 2001-07-03 James J. Hall Portable storage unit for game animals
US7723303B2 (en) 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7144862B2 (en) 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
US8124625B2 (en) 2001-09-14 2012-02-28 Shionogi & Co., Ltd. Method of enhancing the expression of apolipoprotein AI using olefin derivatives
EP2168576A3 (en) 2001-09-14 2010-05-26 Shionogi & Co., Ltd. Tricyclic compounds for treating dyslipidemia and arteriosclerotic diseases
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
KR20070089996A (ko) 2004-12-06 2007-09-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 세동맥의 구조 및 기능의 개선 방법
EP2195331B1 (en) 2007-08-28 2013-11-20 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
WO2009032702A2 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
ES2448567T3 (es) * 2008-10-30 2014-03-14 Circomed Llc Derivados de la tienotriazoldiazepina activos en apo A
PL2902030T3 (pl) 2010-05-14 2017-07-31 Dana-Farber Cancer Institute, Inc. Związki tienotriazolodiazepinowe do leczenia nowotworu
CN103119160B (zh) * 2010-05-14 2016-06-01 达那-法伯癌症研究所 用于调节代谢的组合物和方法
MX354217B (es) 2010-05-14 2018-02-19 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
EP2571875A4 (en) 2010-05-14 2013-10-30 Dana Farber Cancer Inst Inc CONTRACEPTIVE COMPOSITIONS FOR MEN AND METHODS OF USE THEREOF
US9975896B2 (en) 2013-07-25 2018-05-22 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
RU2016122654A (ru) 2013-11-08 2017-12-14 Дана-Фарбер Кэнсер Инститьют, Инк. Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка
EP3099677A4 (en) 2014-01-31 2017-07-26 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
US10793571B2 (en) 2014-01-31 2020-10-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
JP2017506666A (ja) 2014-02-28 2017-03-09 テンシャ セラピューティクス，インコーポレイテッド 高インスリン血症に関連した症状の処置
WO2016018665A1 (en) 2014-07-31 2016-02-04 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
CN106793775B (zh) 2014-08-08 2020-06-02 达纳-法伯癌症研究所股份有限公司 二氢碟啶酮衍生物及其用途
CN106715437A (zh) 2014-08-08 2017-05-24 达纳-法伯癌症研究所股份有限公司 二氮杂环庚烷衍生物及其用途
KR20170068597A (ko) 2014-10-27 2017-06-19 텐샤 세러퓨틱스 인코포레이티드 브로모도메인 저해제
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
RU2018112953A (ru) 2015-09-11 2019-10-14 Дана-Фарбер Кэнсер Инститьют, Инк. Ацетамидтиенотриазолодиазепины и пути их применения
EP3347021A4 (en) 2015-09-11 2019-07-24 Dana-Farber Cancer Institute, Inc. CYANOTHIENOTRIAZOLDIAZEPINE AND USES THEREOF
MX2018006499A (es) 2015-11-25 2018-08-01 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos.
AU2019284971A1 (en) 2018-06-13 2020-12-03 Worg Pharmaceuticals (Zhejiang) Co., Ltd. Preparation of condensed triazepine derivatives and their use as BET inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4155913A (en) * 1973-02-08 1979-05-22 Hoffmann-La Roche Inc. Thienotriazolodiazepine derivatives
PH12303A (en) * 1973-02-08 1979-01-16 Hoffmann La Roche Thienotriazolodiazepine derivatives
JPS50100096A (https=) * 1974-01-08 1975-08-08

Also Published As

Publication number Publication date
JPH11512107A (ja) 1999-10-19
BR9610390A (pt) 1999-07-06
DE69625696D1 (de) 2003-02-13
DK0853480T3 (da) 2003-05-05
CN1101680C (zh) 2003-02-19
MX9801753A (es) 1998-08-30
CA2230477A1 (en) 1997-03-13
EP0853480B1 (en) 2003-01-08
AU725249B2 (en) 2000-10-12
AU6930396A (en) 1997-03-27
CN1195989A (zh) 1998-10-14
WO1997009048A1 (en) 1997-03-13
EP0853480A1 (en) 1998-07-22
US5854238A (en) 1998-12-29
ES2188783T3 (es) 2003-07-01
TR199800406T1 (en) 1998-05-21
KR19990044460A (ko) 1999-06-25
ATE230600T1 (de) 2003-01-15

Similar Documents

Publication Publication Date Title
DE69625696T2 (de) Verwendung eines thienotriazoldiazepins zur erhöhung des apolopoproteins a-i niveaus
DE68903215T2 (de) Hypocholesterolaemische und antiatherosklerotische verwendung von bis-(3,5-di-tertiaerbutyl-4-hydroxyphenylthio)methan.
DE69909775T2 (de) Neue fettanaloge zur behandlung von diabetes
DE69804281T2 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Leberkrankheiten
WO1993021912A1 (de) Verwendung einer omega-3-fettsäuren enthaltenden emulsion zur herstellung eines parenteral zu verabreichenden arzneimittels zur behandlung von entzündlichen erkrankungen
DE69636792T2 (de) Verwendung von l-carnitine und acyl derivaten zur senkung des ceramidspiegels
DE69420776T2 (de) Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer
DE69826674T2 (de) Zusammensetzung, l-carnitin oder alkanoyl l-carnitin und langkettige alkanole enthaltend
DE3781054T2 (de) Die verwendung von d-fenfluramin zur herstellung von arzneimitteln, zur behandlung von depressionen.
DE3035494A1 (de) Carnitin enthaltendes arzneimittel zur behandlung von hyperlipidaemie und hyperlipoproteinaemie, sowie verwendung von carnitin zur herstellung eines solchen arzneimittels
DE3311922C2 (de) Verwendung von substituierten 1,4-Benzochinonen bei der Prophylaxe oder Behandlung von Fibrose
EP0765661A2 (en) Use of docosahexaenoic acid for the manufacture of a medicament for the treatment of glumerulonephritis
WO1987000751A2 (en) Use of oxirancarboxylic acids for the treatment of hyperlipemia
DE69315162T2 (de) Verwendung von L-Carnitine und Acyl-L-Carnitinen zur Behandlung von Patienten die an AIDS-verwandten Syndromen leiden und von asymptomatischen HIV-seropositiven Patienten
DE3873210T2 (de) Verwendung von benzylpyridin-derivaten zur herstellung eines arzneimittels zur behandlung der demenz.
DE3202561A1 (de) Lysinsalze der ((1-benzyl-1h-indazol-3-yl)-oxy)-essigsaeure, verfahren zu deren herstellung und diese enthaltende arzneimittel
DE60216118T2 (de) Sesquiterpenoid-derivate mit adipozytendifferenzierungshemmender wirkung
DE69115528T2 (de) Neue pharmazeutische Verwendungen von Forskolin-Derivaten
DE602004003173T2 (de) Verwendung von konjugierter Linolsäure zur Behandlung der Erkältung
DE69230590T2 (de) Mittel gegen fettleibigkeit
DE3779991T2 (de) Dioxopiperidin-derivate enthaltende anxiolytische zusammensetzungen.
EP0524512B1 (de) Antihypertensive Kombination
DE69413544T2 (de) Reduzierte absorption von fettsäuren
DE69302250T2 (de) Verwendung von Isoquinolinon-Derivaten zur Behandlung von Hyperlipoproteinemia
DE3632201C2 (de) Pharmazeutische Zusammensetzung mit retardierter Freisetzung des Wirkstoffes

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee